Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.

Why Integer Holdings is on investors' radar today

Investor attention around Integer Holdings (ITGR) has been driven by its recent share performance, with the stock up over the past week, month, past 3 months, and year to date.

That move sits against a mixed longer view. The 1 year total return shows a decline, while 3 year and 5 year total returns are positive. This gives you a split picture of how the stock has behaved over different holding periods.

See our latest analysis for Integer Holdings.

Recent trading has been firm, with a 7.73% 90 day share price return and a 19.80% year to date share price return at a current share price of US$91.98. This is set against a 1 year total shareholder return that has declined 24.19% and more modest 3 year and 5 year total shareholder returns of 9.92% and 3.35%, which may indicate that recent momentum is building after a weaker year.

If Integer Holdings is on your watchlist, this can be a good moment to broaden your search and check out 39 healthcare AI stocks

With Integer trading at US$91.98 and sitting at an estimated 31% discount to one intrinsic value model and a 6% discount to analyst targets, you have to ask: is there a mispricing here, or are markets already assuming stronger growth ahead?

Most Popular Narrative: 6% Undervalued

At a last close of US$91.98 versus a narrative fair value of about US$97.56, Integer Holdings is framed as slightly undervalued, with that gap resting on a detailed set of sector and company specific assumptions.

Integer is experiencing robust demand growth, particularly in Cardio & Vascular and electrophysiology end markets, driven by increasing incidence of chronic diseases and the global demographic shift toward an aging population; this is leading to above-market sales growth with guidance for sustained organic revenue acceleration.

The company's strong pipeline of new product launches concentrated in faster-growing categories such as advanced electrophysiology tools and neuromodulation devices positions it to capitalize on industry-wide technological advancements and the shift toward minimally invasive procedures, supporting future revenue and market share expansion.

Read the complete narrative.

Want to see how modest revenue growth, steady margin assumptions and a future earnings multiple come together to back that fair value label? The full narrative spells out the earnings path, the profit profile and the valuation multiple that need to line up to justify the current analyst target, and sets those against specific growth drivers in Integer's key medical segments.